Uric acid elimination in the urine: Pathophysiological implications

Contributions to Nephrology

Volumn 147, Issue , 2005, Pages 132-148

  Marangella, Martino ^a  

^a MAURIZIANO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

ACUTE KIDNEY FAILURE; HUMAN; KIDNEY; LEAD POISONING; METABOLISM; NEPHROLITHIASIS; REVIEW; URINE;

HUMANS; KIDNEY; KIDNEY CALCULI; KIDNEY FAILURE, ACUTE; LEAD POISONING; URIC ACID;

EID: 16644367982     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (77)

1. Bergman F, Dikstein S: Relationship between spectral shifts and structural changes in uric acid and related compounds. J Am Chem Soc 1955;77:691-696.
2. Wu X, Lee CC, Muzny DM, Caskey CT: Urate oxidase: Primary structure and evolutionary implications. Proc Natl Acad Sci USA 1989;86:9412-9416.
3. Becker BF: Towards the physiological function of uric acid. Free Radic Biol Med 1993;14:615-631.
4. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis: Proc Natl Acad Sci USA 1981;78:6858-6862.
5. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I: Uric acid, a natural scavenger of peroxynitrite, ill experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998;95:675-680.
6. Steel TH, Rieselbach RE: The renal mechanism for urate homeostasis ill normal man. Am J Med 1967;43:868-875.
7. Levinson DJ, Sorensen LB: Renal handling of uric acid in normal and gouty subjects: Evidence for a 4-component system. Ann Rheum Dis 1980;39:173-119.
8. Roch-Ramel F, Guisan B, Diezei J: Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 1997;280:839-845.
9. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H : Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417:447-452.
10. Hosoyamada M, Ichida K, Enomoto A, Hosoya T, Endou H: Function and localization of urate transporter 1 in mouse kidney. J Am Soc Nephrol 2004;15:261-268.
11. Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, Hosoya T: Clinical and molecular analysis of patients with renal hypouricemia in Japan - Influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004;15:164-173.
12. Dahan K, Devuyst O, Smaers M, Vertommen D, Loute G, Poux JM, Viron B, Jacquot C, Gagnadoux MF, Chauveau D, Buchler M, Cochat P, Cosyns JP, Mougenot B, Rider MH, Antignac C, Verellen-Dumoulin C, Pirson Y: A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol 2003;14:2883-2893.
13. Leal-Pinto E, Tao W, Richardson M, Knorr B, Abramson RG: Molecular cloning and functional reconstitution of a urate transporter/channel. J Biol Chem 1997;272:617-625.
14. Dahan K, Fuchshuber A, Adamis S, Smaers M, Kroiss S, Loute G, Cosyns JP, Hildebrandt F, Verellen-Dumoulin C, Pirson Y: Familial juvenile hyperuricemic nephropathy and autosomal dominant medullary cystic kidney disease type 2: Two facets of the same disease? J Am Soc Nephrol 2001;12:2348-2357.
15. Lipkowitz MS, Leal-Pinto E, Cohen BE, Abramson RG: Galectin 9 is the sugar-regulated urate transporter/channel UAT. Glycoconj J 2004;19:491-498.
16. Rappaport J, Lipkowitz MS, Abramson RG: Localization and topology of a urate transporter/channel, a galectin, in epithelium-derived cells. Am J Physiol Cell Physiol 2001;281:C1926-C1939.
17. Yu T, Berger L, Sarkozi L, Kaung C: Effects of diuretics on urate and calcium excretion. Arch Intern Med 1981;141:915-919.
18. Reyes AJ: Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003;17:397-414.
19. Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R: The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000;43:103-108.
20. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ: The effect of insulin on renal handling of sodium, potassium, calcium and phosphate in man. J Clin Invest 1975;55:845-855.
21. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E: Effect of insulin on uric acid excretion in humans. Am J Physiol 1995;268:E1-E5.
22. Ter Maaten JC, Voorburg A, Heine RJ, Ter Wee PM, Donker AJ, Gans RO: Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci 1997;92:51-58.
23. Vuorinen-Markkola H, Yki-Jarvinen H: Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994;78:25-29.
24. Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM, Frascerra S, Ciociaro D, Ferrannini E: Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996;9:746-752.
25. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA 2000;16:356-359.
26. Quinones-Galvan A, Ferrannini E: Renal effects of insulin in man. J Nephrol 1997;10:188-191.
27. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlof B; LIFE Study Group: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-1049.
28. Abate N, Chandalia M, Cabo-Chan AV, Moe OW, Sakhaee K: The metabolic syndrome and uric acid nephrolithiasis: Novel features of renal manifestation of insulin resistance. Kidney Int 2004;65:386-392.
29. Berger L, Yu TF: Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med 1975;59:605-613.
30. Linnane JW, Burry AF, Emmerson BT: Urate deposits in the renal medulla. Prevalence and associations. Nephron 1981;29:216-222.
31. Fessel WJ: Renal outcomes of gout and hyperuricemia. Am J Med 1979;67:74-82.
32. Verberckmoes R: Uric acid and the kidney. Oxford Textbook of Clinical Nephrology. Oxford, Oxford Medical Publication, 1992, pp 825-837.
33. Reif MC, Constantiner A, Levitt MF: Chronic gouty nephropathy: A vanishing syndrome? N Engl J Med 1981;304:535-536.
34. Batuman V, Maesaka JK, Haddad B, Tepper E, Landy E, Wedeen RP: The role of lead in gout nephropathy. N Engl J Med 1981;304:520-523.
35. Colleoni N, D'Amico G: Chronic lead accumulation as a possible cause of renal failure in gouty patients. Nephron 1986;44:32-35.
36. Wedeen RP, D'Haese P, Van de Vyver FL, Verpooten GA, De Broe ME: Lead nephropathy. Am J Kidney Dis 1986;8:380-383.
37. Batuman V: Lead nephropathy, gout, and hypertension. Am J Med Sci 1993;305:241-247.
38. Coe FL: Uric acid and calcium oxalate nephrolithiasis. Kidney Int 1983;24:392-396.
39. Finlayson B, Smith LH: Stability of first dissociable proton of uric acid. J Chem Engl Data 1974;19:94.
40. Nakashima M, Uematsu T, Kosuge K, Kanamura M: Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in essential hypertension. Eur J Clin Pharmacol 1992;42:333-335.
41. Hatch M, Freel RW, Shahinfar S, Vaziri ND: Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. J Pharmacol Exp Ther 1996;276:187-193.
42. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal-Re R: Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999;17:1033-1039.
43. Kamper AL, Nielsen AH: Uricosuric effect of losartan in patients with renal transplants. Transplantation 2001;72:671-674.
44. Shahinfar S, Simpson RL, Carides AD, Thiyagarajan B, Nakagawa Y, Umans JG, Parks JH, Coe FL: Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999;56:1879-1885.
45. Sica DA, Schoolwerth AC: Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens 2002;11:475-482.
46. Ito O, Hasegawa Y, Sato K, Mitsui H, Yuda F, Sato H, Ito S, Kudo K: A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide. Hypertens Res 2003;26:509-513.
47. Gonzales-Ortiz M, Mora-Martinez JM, Martinez-Abundis E, Rebeca B, Munoz B: Effect of valsartan on renal handling of uric acid in healthy subjects. J Nephrol 2000;13:125-127.
48. Praga M, Alegre R, Hernandez E, Morales E, Dominguez-Gil B, Carreno A, Andres A: Familial microscopic hematuria caused by hypercalciuria and hyperuricosuria. Am J Kidney Dis 2000;35:141-145.
49. Magen D, Adler L, Mandel H, Efrati E, Zelikovic I: Autosomal recessive renal proximal tubulopathy and hypercalciuria: A new syndrome. Am J Kidney Dis 2004;43:600-606.
50. Ohta T, Sakano T, Ogawa T, Kato J, Awaya Y, Kihara H, Kinoshita Y: Exercise-induced acute renal failure with renal hypouricemia: A case report and a review of the literature. Clin Nephrol 2002;58:313-316.
51. Tanaka M, Itoh K, Matsushita K, Matsushita K, Wakita N, Adachi M, Nonoguchi H, Kitamura K, Hosoyamada M, Endou H, Tomita K: Two male siblings with hereditary renal hypouricemia and exercise-induced ARF. Am J Kidney Dis 2003;42:1287-1292.
52. Hisatome I, Ogino K, Kotake H, Ishiko R, Saito M, Hasegawa J, Mashiba H, Nakamoto S: Cause of persistent hypouricemia in outpatients. Nephron 1989;67:13-16.
53. Yeun JY, Hasbargen JA: Renal hypouricemia: Prevention of exercise-induced acute renal failure and a review of the literature. Am J Kidney Dis 1995;25:937-946.
54. Murakami T, Kawakami H, Fukuda M, Shiigi H: Recurrence of acute renal failure and renal hypouricemia. Pediatr Nephrol 1993;7:772-773.
55. Hisatome I, Tanaka Y, Tsuboi M, Yatsuhashi T, Ogino K, Uchida T, Yamanouchi Y, Shimoyama M, Fujita S, Kinugawa T, Igawa O, Yoshida A, Takeda A, Sato R, Shigemasa C: Excess urate excretion correlates with severely acidic urine in patients with renal hypouricemia. Intern Med 1998;37:726-731.
56. Walls M, Goral S, Stone W: Acute renal failure due to sulfinpyrazone. Am J Med Sci 1998;315:319-321.
57. Marangella M, Petrarulo M, Daniele PG, Sammartano S: LithoRisk: A software for calculating and visualizing nephrolithiasis risk profiles. G Ital Nefrol 2002;19:693-698.
58. Sutor DJ, Wooley SE, Illingworth JJ: A geographical and historical survey of the composition of urinary stones. Br J Urol 1974;46:393-407.
59. Sperling O: Prevalence of uric acid lithiasis. Adv Urol Nephrol 1987;26:9-12.
60. Mandel NS, Mandel GS: Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. J Urol 1989;142:1516-1521.
61. Yoshida O, Okada Y: Epidemiology of urolithiasis in Japan: A chronological and geographical study. Urol Int 1990;45:104-111.
62. Parks JH, Coward M, Coe FL: Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int 1997;51:894-900.
63. Millman S, Strauss AL, Parks JH, Coe FL: Pathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis. Kidney Int 1982;22:366-370.
64. Pak CYC, Sakhaee K, Peterson RD, Poindexter JR, Frawley WH: Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int 2001;60:757-761.
65. Pak CYC: Uric acid nephrolithiasis; in Resnick MI, Pak CYC (eds): Urolithiasis: A medical and surgical reference. Philadelphia, WB Saunders, 1990, pp 105-112.
66. Yu TF, Gutman AB: Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med 1967;67:1133-1148.
67. Coe FL, Kavalach AG: Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med 1974;291:1344-1350.
68. Coe FL, Strauss AL, Tembe V, Le Dun S: Uric acid saturation in calcium nephrolithiasis. Kidney Int 1980;17:662-668.
69. Kamel KS, Cheema-Dhadli S, Halperin ML: Studies on the pathophysiology of the low urine pH in patients with uric acid stones. Kidney Int 2002;61:988-994.
70. Sakhaee K, Adams-Huet B, Moe OW, Pak CYC: Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int 2002;62:971-979.
71. Henneman PH, Wallach S, Dempsey EF: The metabolic defect responsible for uric acid stone formation. J Clin Invest 1962;41:537-542.
72. + excretion in primary gout. J Clin Invest 1965;44:1474-1481.
73. + ion in patients with uric acid calculi. Clin Sci 1965;28:325-342.
74. Falls WF: Comparison of urinary acidification and ammonium excretion in normal and gouty subjects. Metabolism 1972;21:433-445.
75. Abate N, Chandalia M, Cabo-Chan AV, Moe OW, Sakhaee K: The metabolic syndrome and uric acid nephrolithiasis: Novel features of renal manifestation of insulin resistance. Kidney Int 2004;65:386-392.
76. Pak CY, Sakhaee K, Fuller C: Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 1986;30:422-428.
77. Coe FL: Calcium-uric acid nephrolithiasis. Arch Intern Med 1978;138:1090-1093.